Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 34 | 2026 | 559 | 5.210 |
Why?
|
| Colorectal Neoplasms | 31 | 2026 | 642 | 5.200 |
Why?
|
| Occult Blood | 16 | 2025 | 162 | 2.160 |
Why?
|
| Colonoscopy | 14 | 2025 | 265 | 1.990 |
Why?
|
| Mass Screening | 16 | 2026 | 693 | 1.650 |
Why?
|
| Reminder Systems | 4 | 2025 | 76 | 1.100 |
Why?
|
| Aged | 43 | 2026 | 6223 | 0.990 |
Why?
|
| Text Messaging | 3 | 2025 | 38 | 0.970 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 144 | 0.940 |
Why?
|
| Middle Aged | 43 | 2026 | 7954 | 0.930 |
Why?
|
| Humans | 63 | 2026 | 17622 | 0.920 |
Why?
|
| Video Recording | 1 | 2025 | 15 | 0.920 |
Why?
|
| Patient Compliance | 4 | 2020 | 269 | 0.820 |
Why?
|
| Safety-net Providers | 7 | 2025 | 55 | 0.810 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 380 | 0.800 |
Why?
|
| Public Health | 3 | 2020 | 84 | 0.790 |
Why?
|
| Community Health Centers | 5 | 2025 | 56 | 0.760 |
Why?
|
| Male | 46 | 2026 | 10014 | 0.750 |
Why?
|
| Female | 47 | 2026 | 12715 | 0.740 |
Why?
|
| Patient Navigation | 5 | 2025 | 20 | 0.700 |
Why?
|
| Electronic Health Records | 9 | 2020 | 719 | 0.690 |
Why?
|
| Medicaid | 7 | 2025 | 188 | 0.660 |
Why?
|
| Feces | 8 | 2025 | 89 | 0.620 |
Why?
|
| Postal Service | 9 | 2025 | 72 | 0.590 |
Why?
|
| Patient Selection | 3 | 2024 | 181 | 0.550 |
Why?
|
| Rural Population | 3 | 2025 | 58 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2016 | 187 | 0.460 |
Why?
|
| Oregon | 8 | 2025 | 172 | 0.420 |
Why?
|
| Clostridium difficile | 4 | 2016 | 22 | 0.410 |
Why?
|
| Qualitative Research | 5 | 2024 | 290 | 0.380 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 164 | 0.360 |
Why?
|
| Risk Assessment | 6 | 2019 | 1093 | 0.350 |
Why?
|
| Glomerular Filtration Rate | 7 | 2016 | 158 | 0.340 |
Why?
|
| Adult | 18 | 2025 | 7621 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2025 | 135 | 0.330 |
Why?
|
| Diffusion of Innovation | 1 | 2010 | 36 | 0.320 |
Why?
|
| Case Management | 1 | 2010 | 29 | 0.320 |
Why?
|
| Retrospective Studies | 16 | 2020 | 2502 | 0.310 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 54 | 0.310 |
Why?
|
| Kidney Diseases | 4 | 2010 | 54 | 0.300 |
Why?
|
| Northwestern United States | 6 | 2016 | 53 | 0.300 |
Why?
|
| Neoplasms | 2 | 2025 | 457 | 0.290 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 269 | 0.280 |
Why?
|
| Heart Failure | 2 | 2012 | 414 | 0.280 |
Why?
|
| Medicare | 5 | 2022 | 197 | 0.280 |
Why?
|
| United States | 14 | 2025 | 3922 | 0.270 |
Why?
|
| Aged, 80 and over | 15 | 2016 | 1976 | 0.270 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 204 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 64 | 0.250 |
Why?
|
| Primary Health Care | 5 | 2024 | 729 | 0.240 |
Why?
|
| Research Design | 3 | 2019 | 337 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 3 | 2012 | 149 | 0.230 |
Why?
|
| Hospitalization | 2 | 2010 | 831 | 0.230 |
Why?
|
| Hispanic Americans | 4 | 2016 | 370 | 0.230 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 1157 | 0.230 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 346 | 0.230 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 702 | 0.230 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 258 | 0.220 |
Why?
|
| Renal Replacement Therapy | 3 | 2016 | 8 | 0.220 |
Why?
|
| Data Accuracy | 1 | 2024 | 26 | 0.210 |
Why?
|
| Information Dissemination | 1 | 2024 | 50 | 0.210 |
Why?
|
| Prognosis | 7 | 2020 | 609 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 114 | 0.210 |
Why?
|
| Specimen Handling | 1 | 2024 | 25 | 0.210 |
Why?
|
| Clostridium Infections | 2 | 2016 | 13 | 0.210 |
Why?
|
| Rural Health Services | 1 | 2024 | 13 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 13 | 0.200 |
Why?
|
| Blood Pressure | 3 | 2016 | 288 | 0.200 |
Why?
|
| Forecasting | 2 | 2020 | 68 | 0.190 |
Why?
|
| Back Pain | 2 | 2013 | 32 | 0.190 |
Why?
|
| Anemia | 2 | 2012 | 31 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 368 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 31 | 0.160 |
Why?
|
| Vaccination | 1 | 2025 | 726 | 0.160 |
Why?
|
| Hemoglobins | 3 | 2016 | 37 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 208 | 0.140 |
Why?
|
| Program Evaluation | 3 | 2020 | 214 | 0.130 |
Why?
|
| Washington | 4 | 2025 | 388 | 0.130 |
Why?
|
| Models, Statistical | 2 | 2016 | 171 | 0.130 |
Why?
|
| Models, Biological | 1 | 2016 | 27 | 0.130 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 403 | 0.130 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 65 | 0.130 |
Why?
|
| Interviews as Topic | 5 | 2017 | 324 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1295 | 0.120 |
Why?
|
| Risk Management | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2015 | 2502 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.120 |
Why?
|
| Cross Infection | 1 | 2016 | 24 | 0.120 |
Why?
|
| Risk | 2 | 2014 | 492 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2020 | 189 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2014 | 248 | 0.110 |
Why?
|
| Drug Utilization | 2 | 2012 | 119 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 1038 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 42 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 866 | 0.110 |
Why?
|
| Individuality | 1 | 2014 | 2 | 0.110 |
Why?
|
| Sodium | 1 | 2014 | 14 | 0.110 |
Why?
|
| Age Factors | 5 | 2016 | 874 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 19 | 0.100 |
Why?
|
| Referral and Consultation | 3 | 2021 | 161 | 0.100 |
Why?
|
| Cost Savings | 2 | 2011 | 20 | 0.100 |
Why?
|
| Health Literacy | 1 | 2014 | 38 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 56 | 0.100 |
Why?
|
| Testosterone | 1 | 2013 | 21 | 0.100 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 23 | 0.100 |
Why?
|
| Incidence | 5 | 2020 | 1278 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2014 | 112 | 0.100 |
Why?
|
| Aging | 1 | 2014 | 159 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 228 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 23 | 0.090 |
Why?
|
| Benchmarking | 1 | 2012 | 34 | 0.090 |
Why?
|
| Preventive Health Services | 1 | 2014 | 147 | 0.090 |
Why?
|
| Low Back Pain | 1 | 2012 | 58 | 0.090 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 63 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2022 | 1161 | 0.090 |
Why?
|
| Health Expenditures | 1 | 2012 | 72 | 0.090 |
Why?
|
| Laboratories | 1 | 2011 | 19 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 124 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 35 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 16 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 211 | 0.080 |
Why?
|
| Systole | 3 | 2016 | 21 | 0.080 |
Why?
|
| Telephone | 2 | 2023 | 159 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 237 | 0.080 |
Why?
|
| Quality of Life | 2 | 2025 | 505 | 0.080 |
Why?
|
| Lisinopril | 1 | 2010 | 6 | 0.080 |
Why?
|
| Young Adult | 5 | 2016 | 2538 | 0.080 |
Why?
|
| Hyperkalemia | 1 | 2010 | 15 | 0.080 |
Why?
|
| California | 3 | 2025 | 2433 | 0.080 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 84 | 0.070 |
Why?
|
| Health Services Research | 1 | 2010 | 201 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 308 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 323 | 0.070 |
Why?
|
| Adolescent | 3 | 2025 | 3625 | 0.070 |
Why?
|
| Colorado | 3 | 2014 | 170 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 446 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2010 | 256 | 0.070 |
Why?
|
| Comorbidity | 3 | 2014 | 552 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2010 | 398 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 26 | 0.060 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 55 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2007 | 75 | 0.060 |
Why?
|
| Fractures, Bone | 1 | 2007 | 93 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 121 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 214 | 0.060 |
Why?
|
| Communication | 2 | 2019 | 181 | 0.060 |
Why?
|
| Los Angeles | 1 | 2026 | 150 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 207 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 120 | 0.050 |
Why?
|
| Pandemics | 1 | 2026 | 295 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 545 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 43 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 599 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 2 | 2012 | 14 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 228 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 143 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 603 | 0.040 |
Why?
|
| Health Services | 2 | 2012 | 110 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 104 | 0.040 |
Why?
|
| Health Behavior | 2 | 2014 | 348 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 59 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 631 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 3291 | 0.040 |
Why?
|
| Biomarkers | 2 | 2012 | 302 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2020 | 20 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 65 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2012 | 276 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 830 | 0.030 |
Why?
|
| Patient Participation | 1 | 2019 | 124 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2017 | 17 | 0.030 |
Why?
|
| Awareness | 1 | 2017 | 17 | 0.030 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leadership | 1 | 2017 | 36 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1107 | 0.030 |
Why?
|
| Albuminuria | 1 | 2016 | 39 | 0.030 |
Why?
|
| Health Promotion | 1 | 2019 | 293 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1251 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 103 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 13 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 3 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 69 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 163 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 179 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 1296 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 40 | 0.030 |
Why?
|
| Comprehension | 1 | 2014 | 19 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 86 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 25 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 45 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 65 | 0.030 |
Why?
|
| Language | 1 | 2014 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 363 | 0.030 |
Why?
|
| Tadalafil | 1 | 2013 | 1 | 0.020 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2013 | 1 | 0.020 |
Why?
|
| Carbolines | 1 | 2013 | 1 | 0.020 |
Why?
|
| Sulfones | 1 | 2013 | 1 | 0.020 |
Why?
|
| Triazines | 1 | 2013 | 3 | 0.020 |
Why?
|
| Urological Agents | 1 | 2013 | 2 | 0.020 |
Why?
|
| Purines | 1 | 2013 | 2 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 4 | 0.020 |
Why?
|
| Sildenafil Citrate | 1 | 2013 | 3 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 7 | 0.020 |
Why?
|
| Androgens | 1 | 2013 | 14 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 20 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 92 | 0.020 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2012 | 92 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 319 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 34 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 73 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 96 | 0.020 |
Why?
|
| Health Records, Personal | 1 | 2011 | 10 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 103 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 686 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 169 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 44 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 64 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 37 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2012 | 213 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 302 | 0.020 |
Why?
|
| Decision Making | 1 | 2012 | 177 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 266 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 420 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 152 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 141 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 252 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 319 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 300 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 321 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2009 | 2 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 197 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1228 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 507 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1455 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 54 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 96 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2485 | 0.010 |
Why?
|
Concepts
(241)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->